OXA (17-33)
Need Assistance?
  • US & Canada:
    +
  • UK: +

OXA (17-33)

* Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.

OXA (17-33) is a peptide orexin OX1 receptor agonist with EC50 value of 8.29 nM. It is a drug candidate for the treatment of heart failure and hypertension.

Category
Peptide Inhibitors
Catalog number
BAT-010276
CAS number
343268-91-7
Molecular Formula
C79H125N23O22
Molecular Weight
1749
OXA (17-33)
IUPAC Name
(4S)-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[2-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S,3S)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-2-oxoethyl]amino]-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-5-oxopentanoic acid
Synonyms
Orexin A (17-33) trifluoroacetate salt H-Tyr-Glu-Leu-Leu-His-Gly-Ala-Gly-Asn-His-Ala-Ala-Gly-Ile-Leu-Thr-Leu-NH2 trifluoroacetate salt; BDBM50445183
Appearance
White Lyophilized Solid
Purity
>97%
Density
1.3±0.1 g/cm3
Boiling Point
2099.4±65.0°C at 760 mmHg
Sequence
YELLHGAGNHAAGILTL
Storage
Store at -20°C
InChI
InChI=1S/C79H125N23O22/c1-15-41(10)64(78(123)100-55(25-40(8)9)77(122)102-65(45(14)103)79(124)95-52(66(82)111)22-37(2)3)101-62(108)34-86-68(113)43(12)91-69(114)44(13)92-73(118)57(28-48-31-84-36-89-48)99-76(121)58(29-59(81)105)93-61(107)33-85-67(112)42(11)90-60(106)32-87-71(116)56(27-47-30-83-35-88-47)98-75(120)54(24-39(6)7)97-74(119)53(23-38(4)5)96-72(117)51(20-21-63(109)110)94-70(115)50(80)26-46-16-18-49(104)19-17-46/h16-19,30-31,35-45,50-58,64-65,103-104H,15,20-29,32-34,80H2,1-14H3,(H2,81,105)(H2,82,111)(H,83,88)(H,84,89)(H,85,112)(H,86,113)(H,87,116)(H,90,106)(H,91,114)(H,92,118)(H,93,107)(H,94,115)(H,95,124)(H,96,117)(H,97,119)(H,98,120)(H,99,121)(H,100,123)(H,101,108)(H,102,122)(H,109,110)/t41-,42-,43-,44-,45+,50-,51-,52-,53-,54-,55-,56-,57-,58-,64-,65-/m0/s1
InChI Key
JPRBZUXULYLVPJ-HYNYKCRDSA-N
Canonical SMILES
CCC(C)C(C(=O)NC(CC(C)C)C(=O)NC(C(C)O)C(=O)NC(CC(C)C)C(=O)N)NC(=O)CNC(=O)C(C)NC(=O)C(C)NC(=O)C(CC1=CN=CN1)NC(=O)C(CC(=O)N)NC(=O)CNC(=O)C(C)NC(=O)CNC(=O)C(CC2=CN=CN2)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCC(=O)O)NC(=O)C(CC3=CC=C(C=C3)O)N
1. Development of disulfide-functionalized peptides covalently binding G protein-coupled receptors
Jürgen Einsiedel, Maximilian F Schmidt, Harald Hübner, Peter Gmeiner Bioorg Med Chem . 2022 May 1;61:116720. doi: 10.1016/j.bmc.2022.116720.
A broadly applicable synthesis of peptides incorporating mixed disulfides between cysteine and homocysteine and cysteamine was developed. The method was established using pharmacologically relevant G protein-coupled receptor (GPCR) ligands including the μ-receptor agonist Dmt-DALDA and extended to the orexin derivative Oxa(17-33) and NT(8-13), the C-terminal hexapeptide of neurotensin. The newly developed NT(8-13) analog 6b incorporating an S-functionalized homocysteine revealed covalent binding of the neurotensin receptor 1 (NTSR1) in a radioligand depletion study.
2. Choline-Sigma-1R as an Additional Mechanism for Potentiation of Orexin by Cocaine
Eugen Brailoiu, G Cristina Brailoiu, Pingwei Zhao, Jeffrey L Barr Int J Mol Sci . 2021 May 13;22(10):5160. doi: 10.3390/ijms22105160.
Orexin A, an endogenous peptide involved in several functions including reward, acts via activation of orexin receptors OX1and OX2, Gq-coupled GPCRs. We examined the effect of a selective OX1agonist, OXA (17-33) on cytosolic calcium concentration, [Ca2+]i, in neurons of nucleus accumbens, an important area in the reward circuit. OXA (17-33) increased [Ca2+]iin a dose-dependent manner; the effect was prevented by SB-334867, a selective OX1receptors antagonist. In Ca2+-free saline, the OXA (17-33)-induced increase in [Ca2+]iwas not affected by pretreatment with bafilomycin A1, an endo-lysosomal calcium disrupter, but was blocked by 2-APB and xestospongin C, antagonists of inositol-1,4,5-trisphosphate (IP3) receptors. Pretreatment with VU0155056, PLD inhibitor, or BD-1047 and NE-100, Sigma-1R antagonists, reduced the [Ca2+]iresponse elicited by OXA (17-33). Cocaine potentiated the increase in [Ca2+]iby OXA (17-33); the potentiation was abolished by Sigma-1R antagonists. Our results support an additional signaling mechanism for orexin A-OX1via choline-Sigma-1R and a critical role for Sigma-1R in the cocaine-orexin A interaction in nucleus accumbens neurons.
3. (2E,25E)-11,14,17,33,36,39,42-Hepta-oxa-penta-cyclo-[41.4.0.0.0.0]hepta-tetra-conta-1(43),2,5(10),6,8,18,20,22,25,27,29,31,44,46-tetra-decaene-4,24-dione
Truong Hong Hieu, Victor N Khrustalev, Le Tuan Anh, Anatoly T Soldatenkov, Svetlana A Soldatova Acta Crystallogr Sect E Struct Rep Online . 2011 May 1;67(Pt 5):o1128-9. doi: 10.1107/S1600536811013201.
The title compound, C(40)H(40)O(9), is a product of the double crotonic condensation of bis-(2-acetyl-phen-oxy)-3-oxapentane with bis-(2-formyl-phen-oxy)-3,6-dioxaoctane. The title macromolecule includes the 31-crown-7-ether skeletal unit and adopts a saddle-like conformation. The two ethyl-ene fragments have E configurations. The volume of the inter-nal cavity of the macrocycle is approximately 125 Å(3). In the crystal, the mol-ecules are arranged at van der Waals distances.
Online Inquiry
Verification code
Inquiry Basket